戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 thogenesis of asthma and chronic obstructive pulmonary disorder.
2 nd is linked to asthma and an array of extra-pulmonary disorders.
3 ucus hyperproduction associated with chronic pulmonary disorders.
4 eristics of both obstructive and restrictive pulmonary disorders.
5 de developing new therapeutic strategies for pulmonary disorders.
6  representing pathologically related primary pulmonary disorders.
7 implicated in a number of cardiovascular and pulmonary disorders.
8 therapeutic option for a number of end-stage pulmonary disorders.
9 ful targets for cell or gene replacement for pulmonary disorders.
10 icated in human disease processes, including pulmonary disorders.
11 n implicated in the etiology of a variety of pulmonary disorders.
12 d in subjects with CF and other inflammatory pulmonary disorders.
13 onates and children with diverse cardiac and pulmonary disorders.
14 tial diagnostic tool in the study of various pulmonary disorders.
15 cation, accurate diagnosis and monitoring of pulmonary disorders.
16 s are implicated in the pathogenesis of many pulmonary disorders.
17 nt of advanced therapeutic interventions for pulmonary disorders.
18 s to benefit patients with acute and chronic pulmonary disorders.
19 epresents a diverse and challenging group of pulmonary disorders.
20 enetic modifications that might translate to pulmonary disorders.
21 such as dependence/addiction, psychosis, and pulmonary disorders.
22 n comorbidities included chronic obstructive pulmonary disorder (15 patients [15.6%]), hypertension (
23 , many features are reminiscent of the fatal pulmonary disorder alveolar capillary dysplasia.
24 s suffering from asthma, chronic obstructive pulmonary disorder and stroke, and are promising in area
25 ools but also the rapid detection of chronic pulmonary disorders and infections.
26 ransplantation or during treatment of severe pulmonary disorders and sepsis.
27 ells are effectors of injury in a variety of pulmonary disorders and syndromes.
28 ch as periodontitis, multiple sclerosis, and pulmonary disorders), and discuss its potential as a the
29 well as cystic fibrosis, chronic obstructive pulmonary disorder, and asthma in the pulmonary tissues.
30 nosinusitis, asthma, and chronic obstructive pulmonary disorder are characterized by inflammation and
31 , diabetes, current smoking, and obstructive pulmonary disorders are also important independent risk
32                                              Pulmonary disorders are the most frequent cause of death
33 deficient (SP-C -/-) mice developed a severe pulmonary disorder associated with emphysema, monocytic
34    Eosinophilic lung diseases are a group of pulmonary disorders associated with peripheral or tissue
35 resent future therapies for life-threatening pulmonary disorders but are limited by technical challen
36 nflammation and, for example, is involved in pulmonary disorders, can regulate cellular migration, an
37 al lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or
38 life-saving intervention for several primary pulmonary disorders complicated by severe lung dysfuncti
39       Mediating pathways shared by all three pulmonary disorders favor innate immune and inflammation
40 brosis (IPF) is a chronic fibroproliferative pulmonary disorder for which there are currently no trea
41 earch investigations of pediatric airway and pulmonary disorders for nearly 25 years.
42  stress and its depletion in humans leads to pulmonary disorders, Gcn2 can also contribute to the pro
43     Gene therapy as a treatment modality for pulmonary disorders has attracted significant interest o
44        Cystic fibrosis (CF), a common lethal pulmonary disorder in Caucasians, is caused by mutations
45 fibrosis, the most commonly inherited lethal pulmonary disorder in Caucasians, is caused by mutations
46 and has found application in a wide range of pulmonary disorders in humans and animal model analogs.
47 tures and mechanisms of renal dysfunction in pulmonary disorders in relation to respiratory acidosis,
48 o the pathogenesis of many acute and chronic pulmonary disorders, including bronchopulmonary dysplasi
49 his article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-
50 opment of various cutaneous; intestinal; and pulmonary disorders, including psoriasis, inflammatory b
51       Lymphangioleiomyomatosis (LAM), a rare pulmonary disorder, manifests as an abnormal neoplastic
52                                              Pulmonary disorders, notably highlighted by the global i
53 ell homeostasis underlie the pathogenesis of pulmonary disorders previously considered idiopathic, pr
54 understanding of the pathogenesis of diverse pulmonary disorders previously considered idiopathic.
55 cardiopulmonary dysfunction during and after pulmonary disorders such as acute lung injury.
56     Fibrosis and apoptosis are juxtaposed in pulmonary disorders such as asthma and the interstitial
57 ng disease (ILD) represents a large group of pulmonary disorders that are often progressive and assoc
58    Goblet cell metaplasia accompanies common pulmonary disorders that are prone to recurrent viral in
59 tients who would benefit from LT, especially pulmonary disorders that have been reported to resolve p
60 and mechanical ventilation for PCP and other pulmonary disorders was associated with a high mortality
61 romise for cell-based therapies for neonatal pulmonary disorders, whether EPCs can be derived from pl
62  Absence of SP-C caused a severe progressive pulmonary disorder with histologic features consistent w